BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32547841)

  • 21. Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization.
    Busner J; Pandina G; Domingo S; Berger AK; Acosta MT; Fisseha N; Horrigan J; Ivkovic J; Jacobson W; Revicki D; Villalta-Gil V
    Innov Clin Neurosci; 2021; 18(10-12):15-22. PubMed ID: 35096477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electroencephalographic prodromal markers of dementia across conscious states in Parkinson's disease.
    Latreille V; Carrier J; Gaudet-Fex B; Rodrigues-Brazète J; Panisset M; Chouinard S; Postuma RB; Gagnon JF
    Brain; 2016 Apr; 139(Pt 4):1189-99. PubMed ID: 26912643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How is research publishing going to progress in the next 20 years?: transcription of session for editors, associate editors, publishers and others with an interest in scientific publishing held at IADR meeting in Seattle on Wednesday, 20 March 2013.
    Eaton KA; Rex Holland G; Giannobile WV; Hancocks S; Robinson PG; Lynch CD
    J Dent; 2014 Mar; 42(3):219-28. PubMed ID: 24440711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Linked Clinical Trials initiative (LCT) for Parkinson's disease.
    Brundin P; Wyse RK
    Eur J Neurosci; 2019 Feb; 49(3):307-315. PubMed ID: 30269406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the progression of Parkinson's disease: a metabolic network approach.
    Eckert T; Tang C; Eidelberg D
    Lancet Neurol; 2007 Oct; 6(10):926-32. PubMed ID: 17884682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mahlknecht P; Gasperi A; Djamshidian A; Kiechl S; Stockner H; Willeit P; Willeit J; Rungger G; Poewe W; Seppi K
    Mov Disord; 2018 Mar; 33(3):405-413. PubMed ID: 29436728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Michael J. Fox Foundation for Parkinson's Research Strategy to Advance Therapeutic Development of PINK1 and Parkin.
    Padmanabhan S; Polinski NK; Menalled LB; Baptista MAS; Fiske BK
    Biomolecules; 2019 Jul; 9(8):. PubMed ID: 31344817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
    Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
    Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sleep behavior disorder (RBD) in synucleionopaties].
    Glas Srp Akad Nauka Med; 2009; (50):7-15. PubMed ID: 20666111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RBD: a red flag for cognitive impairment in Parkinson's disease?
    Lin YQ; Chen SD
    Sleep Med; 2018 Apr; 44():38-44. PubMed ID: 29530367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.
    Murck H; Laughren T; Lamers F; Picard R; Walther S; Goff D; Sainati S
    Innov Clin Neurosci; 2015; 12(3-4):26S-40S. PubMed ID: 25977838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
    Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
    BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical REM sleep behavior disorder and motor subtypes in Parkinson's disease: a questionnaire-based study.
    Aygun D; Turkel Y; Onar MK; Sunter T
    Clin Neurol Neurosurg; 2014 Apr; 119():54-8. PubMed ID: 24635926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient Perspectives on Deep Brain Stimulation Clinical Research in Early Stage Parkinson's Disease.
    Heusinkveld L; Hacker M; Turchan M; Bollig M; Tamargo C; Fisher W; McLaughlin L; Martig A; Charles D
    J Parkinsons Dis; 2017; 7(1):89-94. PubMed ID: 27911344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rehabilitation of older people with Parkinson's disease: an innovative protocol for RCT study to evaluate the potential of robotic-based technologies.
    Bevilacqua R; Maranesi E; Di Rosa M; Luzi R; Casoni E; Rinaldi N; Baldoni R; Lattanzio F; Di Donna V; Pelliccioni G; Riccardi GR
    BMC Neurol; 2020 May; 20(1):186. PubMed ID: 32404132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palliative care for Parkinson's disease: suggestions from a council of patient and carepartners.
    Hall K; Sumrall M; Thelen G; Kluger BM;
    NPJ Parkinsons Dis; 2017; 3():16. PubMed ID: 28649616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Special Challenges in Pediatric Drug Development: First of Three Sets of Expanded Proceedings from the ISCTM Autumn Conference on Pediatric Drug Development.
    Harvey PD; Busner J; Pandina G; Taylor HG; Grabb M; Jimenez-Shahed J
    Innov Clin Neurosci; 2023; 20(1-3):13-17. PubMed ID: 37122579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.